The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2021 | BTK inhibitors for CLL at EHA 2021
Lydia Scarfò, MD, Vita-Salute San Raffaele University & IRCCS San Raffaele Scientific Institute, Milan, Italy, discusses exciting updates on BTK inhibitors for chronic lymphocytic leukemia (CLL) from the virtual European Hematology Association (EHA) meeting 2021. In particular, Dr Scarfò highlights a direct comparison between acalabrutinib and ibrutinib in patients with relapsed/refractory CLL and associated cardiac toxicities. Dr Scarfò also talks on the CAPITIVATE study (NCT02910583) and a study from the HOVON group, both of which are investigating measurable residual disease (MRD)-driven treatment with ibrutinib and venetoclax. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
Disclosures
Lydia Scarfo, MD, has participated in advisory boards with AbbVie and Janssen and in educational activities with AstraZeneca.
